Julie Lang, MD, discusses real-world outcomes of the neoadjuvant KEYNOTE-522 regimen in patients with early-stage triple-negative breast cancer. Watch more here: https://hubs.li/Q036f4kJ0 | OncLive
0:50
FacebookOncLive
Julie Lang, MD, discusses real-world outcomes of the neoadjuvant KEYNOTE-522 regimen in patients with early-stage triple-negative breast cancer. Watch more here:
OncLive. . Julie Lang, MD, discusses real-world outcomes of the neoadjuvant KEYNOTE-522 regimen in patients with early-stage triple-negative breast cancer. Watch more here: https://hubs.li/Q036f4kJ0
121 viewsFeb 12, 2025
Pembrolizumab Uses
How Tolerable is Pembrolizumab/Paclitaxel/Bevacizumab in PROC? | CancerNetwork
How Tolerable is Pembrolizumab/Paclitaxel/Bevacizumab in PROC? | CancerNetwork
cancernetwork.com
2 months ago
Understanding the Pembrolizumab Treatment Combo in Platinum-Resistant Ovarian Cancers | Oncology Nursing News
Understanding the Pembrolizumab Treatment Combo in Platinum-Resistant Ovarian Cancers | Oncology Nursing News
oncnursingnews.com
2 months ago
Lenvatinib Plus Pembrolizumab in Endometrial Cancer After Neoadjuvant/Adjuvant Therapy | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Lenvatinib Plus Pembrolizumab in Endometrial Cancer After Neoadjuvant/Adjuvant Therapy | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
targetedonc.com
4 months ago
Top videos
🩷 Early-Stage Triple Negative Breast Cancer (TNBC) ✔️ Sa KEYNOTE-522, mas mataas ang pCR sa chemo pembrolizumab (~65%) kumpara sa chemo alone (~51%). ✔️ Mas bumaba ang risk ng recurrence at mas gumanda ang event-free survival. ✔️ Kung chemo lang ang kaya — effective pa rin ito. ✔️ Kung may residual disease, may dagdag na proteksyon ang capecitabine (CREATE-X trial). ✔️ Huwag kalimutan ang breast tissue marker bago chemo para mas accurate at safe ang breast-conserving surgery. 🩺 Hindi pare-pare
2:45
🩷 Early-Stage Triple Negative Breast Cancer (TNBC) ✔️ Sa KEYNOTE-522, mas mataas ang pCR sa chemo pembrolizumab (~65%) kumpara sa chemo alone (~51%). ✔️ Mas bumaba ang risk ng recurrence at mas gumanda ang event-free survival. ✔️ Kung chemo lang ang kaya — effective pa rin ito. ✔️ Kung may residual disease, may dagdag na proteksyon ang capecitabine (CREATE-X trial). ✔️ Huwag kalimutan ang breast tissue marker bago chemo para mas accurate at safe ang breast-conserving surgery. 🩺 Hindi pare-pare
FacebookDr. Emmeline De Los Santos-
2K views2 months ago
Dr. Rugo on the Results of the KEYNOTE-522 Trial in TNBC | OncLive
Dr. Rugo on the Results of the KEYNOTE-522 Trial in TNBC | OncLive
onclive.com
May 21, 2020
Watch Peter Schmid, MD, PhD, FRCP, of Barts Cancer Insitute discuss updated KEYNOTE-522 data showing that pembrolizumab plus chemotherapy improves EFS in early-stage #TNBC. https://www.onclive.com/view/dr-schmid-on-pembrolizumab-plus-chemotherapy-in-high-risk-early-stage-tnbc | OncLive
1:55
Watch Peter Schmid, MD, PhD, FRCP, of Barts Cancer Insitute discuss updated KEYNOTE-522 data showing that pembrolizumab plus chemotherapy improves EFS in early-stage #TNBC. https://www.onclive.com/view/dr-schmid-on-pembrolizumab-plus-chemotherapy-in-high-risk-early-stage-tnbc | OncLive
FacebookOncLive
55 viewsDec 4, 2024
Pembrolizumab Side Effects
Pembrolizumab (Keytruda): How It Works, Side Effects & What Patients Should Know
14:04
Pembrolizumab (Keytruda): How It Works, Side Effects & What Patients Should Know
YouTubeDEMIRxCARE
43 views4 months ago
💊What is PEMBROLIZUMAB?. Mechanism of Action, Dosage and Side Effects of Pembrolizumab (KEYTRUDA)💊
13:24
💊What is PEMBROLIZUMAB?. Mechanism of Action, Dosage and Side Effects of Pembrolizumab (KEYTRUDA)💊
YouTubeMedicines/Diseases
1.6K viewsJun 4, 2020
Keytruda (pembrolizumab) Benefits & Side effects
1:19
Keytruda (pembrolizumab) Benefits & Side effects
YouTubeariflive
40 views10 months ago
🩷 Early-Stage Triple Negative Breast Cancer (TNBC) ✔️ Sa KEYNOTE-522, mas mataas ang pCR sa chemo pembrolizumab (~65%) kumpara sa chemo alone (~51%). ✔️ Mas bumaba ang risk ng recurrence at mas gumanda ang event-free survival. ✔️ Kung chemo lang ang kaya — effective pa rin ito. ✔️ Kung may residual disease, may dagdag na proteksyon ang capecitabine (CREATE-X trial). ✔️ Huwag kalimutan ang breast tissue marker bago chemo para mas accurate at safe ang breast-conserving surgery. 🩺 Hindi pare-pare
2:45
🩷 Early-Stage Triple Negative Breast Cancer (TNBC) ✔️ Sa KEYNOTE-522, mas mataas ang pCR sa chemo pembrolizumab (~65%) kumpara sa chemo alone (~51%). ✔️ Mas bumaba ang risk ng recurrence at mas gumanda ang event-free survival. ✔️ Kung chemo lang ang kaya — effective pa rin ito. ✔️ Kung may residual disease, may dagdag na proteksyon ang capecitabine (CREATE-X trial). ✔️ Huwag kalimutan ang breast tissue marker bago chemo para mas accurate at safe ang breast-conserving surgery. 🩺 Hindi pare-pare
2K views2 months ago
FacebookDr. Emmeline De Los Santos- Cancer Surgeon …
Dr. Rugo on the Results of the KEYNOTE-522 Trial in TNBC | OncLive
Dr. Rugo on the Results of the KEYNOTE-522 Trial in TNBC | OncLive
May 21, 2020
onclive.com
Watch Peter Schmid, MD, PhD, FRCP, of Barts Cancer Insitute discuss updated KEYNOTE-522 data showing that pembrolizumab plus chemotherapy improves EFS in early-stage #TNBC. https://www.onclive.com/view/dr-schmid-on-pembrolizumab-plus-chemotherapy-in-high-risk-early-stage-tnbc | OncLive
1:55
Watch Peter Schmid, MD, PhD, FRCP, of Barts Cancer Insitute discuss updated KEYNOTE-522 data showing that pembrolizumab plus chemotherapy improves EFS in early-stage #TNBC. https://www.onclive.com/view/dr-schmid-on-pembrolizumab-plus-chemotherapy-in-high-risk-early-stage-tnbc | OncLive
55 viewsDec 4, 2024
FacebookOncLive
KEYNOTE-522: Neoadjuvant and Adjuvant Pembrolizumab in TNBC | OncLive
KEYNOTE-522: Neoadjuvant and Adjuvant Pembrolizumab in TNBC | OncLive
Jun 1, 2022
onclive.com
KEYNOTE-522: Event-Free Survival With Neoadjuvant and Adjuvant Pembrolizumab in TNBC | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
6:31
KEYNOTE-522: Event-Free Survival With Neoadjuvant and Adjuvant Pembrolizumab in TNBC | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Dec 15, 2023
targetedonc.com
KEYNOTE-522: pembrolizumabe em pacientes com câncer de mama triplo negativo inicial - Oncologia Brasil
KEYNOTE-522: pembrolizumabe em pacientes com câncer de mama triplo negativo inicial - Oncologia Brasil
Dec 9, 2021
oncologiabrasil.com.br
Dr Lang on Real-World Outcomes With the KEYNOTE-522 Regimen in Early-Stage TNBC | OncLive
Dr Lang on Real-World Outcomes With the KEYNOTE-522 Regimen in Early-Stage TNBC | OncLive
Feb 11, 2025
onclive.com
4:20
KEYNOTE-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer
4.5K viewsOct 25, 2023
YouTubeVJOncology
0:53
KEYNOTE-522 Demonstrates Potential for Immunotherapy in Triple-Negative Breast Cancer
540 viewsOct 31, 2019
YouTubeTargeted Oncology
4:54
KEYNOTE-522 updates: Pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast...
721 viewsJan 7, 2020
YouTubeecancer
13:26
Newly diagnosed with Triple Negative Breast Cancer
1.3K views4 months ago
YouTubeLaura G
5:55
Positive KEYNOTE-522 Overall Survival Results in TNBC | AJMC
Sep 16, 2024
ajmc.com
9:47
Immunotherapy in Early Breast Cancer: Hope or Hype?
1.4K viewsJun 29, 2024
YouTubeCancer Treatment Updates
14:06
Recap of chemo side effects from infusion #3 of Keynote 522 treatment plan for TNBC
335 views3 months ago
YouTubeLaura G
SABCS 2022 Post Hoc Analysis of Adjuvant RT in the Phase 3 KEYNOTE-522 Study: Neoadjuvant Pembro Chemo vs. Placebo Chemo Followed by Adjuvant Pembro vs. Placebo for Early TNBC
Dec 21, 2022
vumedi.com
1:37
How to adapt the KEYNOTE-522 without cyclophosphamide
170 views2 weeks ago
YouTubeClube da Mama
4:50
Triple Negative Breast Cancer Update: Immunotherapy in stage 2-3 TNBC (KEYNOTE 522 Update)
3.7K viewsSep 17, 2024
YouTubeEleonora Teplinsky, MD
14:21
Halftime Recap Of Chemotherapy for Triple Negative Breast Cancer
1.2K views2 months ago
YouTubeLaura G
5:01
KEYNOTE-522: final OS findings of pembrolizumab and chemotherapy in TNBC
3.1K viewsSep 16, 2024
YouTubeVJOncology
15:53
SGBCC 2023丨胡夕春教授：早期三阴性乳腺癌免疫治疗达共识，KEYNOTE-522（新）辅助治疗方案立标准_腾讯新闻
Apr 19, 2023
qq.com肿瘤瞭望
34:12
Keynote-522
911 viewsFeb 3, 2023
YouTubeDr. Mohammed Fathy
0:52
Immunotherapy - keytruda. Finishing keynote 522 for TNBC. #breastcancerin30s ##triplenegativebreastcaner #breastcancerawareness
883 viewsApr 9, 2024
TikTokcutiecuban2.0
3:09
KEYNOTE-522: Neoadjuvant and adjuvant pembrolizumab for early TNBC
2.2K viewsSep 22, 2021
YouTubeVJOncology
2:27
Overall Survival with Pembrolizumab in Breast Cancer | NEJM
3K viewsNov 28, 2024
YouTubeNEJM Group
Dr. Costa on the Implications of the KEYNOTE-522 Trial in TNBC | OncLive
Feb 15, 2023
onclive.com
11:45
SABCS Snippets: KEYNOTE-522 Phase 3 Results
660 viewsMay 29, 2024
YouTubeSan Antonio Breast Cancer Symposium
9:02
Phase 3 KEYNOTE-522 results: pembro/chemo neoadjuvant, pembro adjuvant in early TNBC
2.4K viewsSep 29, 2019
YouTubeVJOncology
22:11
Triple Negative Breast Cancer (TNBC) Treatment Algorithm: Dr. Tiffany Traina
4.6K views2 months ago
YouTubeOncBrothers: Practice-Changing Cancer Discu…
ESMO 2024 Summary: Breast Cancer Highlights - KEYNOTE-522, NATALEE, DESTINY-BREAST12, and CAPItello-290
Sep 24, 2024
vumedi.com
See more